HNL Lab Medicine Announces Strategic Preferred Partnership with bioMérieux
HNL Lab Medicine is excited to announce a Strategic Preferred Partnership with bioMérieux, a world leader in the field of in vitro diagnostics since 1963. This forward-looking alliance is designed to optimize lab operations, enhance patient care, and meet the growing demands of modern healthcare.
“This partnership is a game-changer for our lab operations and our commitment to excellence,” shared Warren Erdmann, Chief Operating Officer at HNL Lab Medicine. “Partnering with bioMérieux, whose expertise in diagnostics perfectly complements our focus on operational excellence, empowers us to streamline testing processes and deliver even faster, more reliable results.” Erdmann highlighted how the collaboration would help address critical supply needs, with bioMérieux’s nearby location facilitating rapid access to essential resources and expertise.
By bringing together HNL Lab Medicine’s clinical precision and bioMérieux’s cutting-edge testing solutions the partnership will drive innovation in lab workflows and support improvements in patient outcomes. This synergy not only advances HNL Lab Medicine’s mission but also pushes industry standards for quality and efficiency.
“Strategic partnerships are core to bioMérieux’s mission to improve public health through in vitro diagnostics,” said Ben W. Andrews, bioMérieux Vice President, U.S. Clinical Operations Sales. “We are also committed to working collaboratively with our customers on the optimization of their laboratory operations for efficient and effective utilization of our products. This collaboration with HNL highlights both organizations’ commitment to advancing infectious disease diagnostic solutions to drive healthier communities and improve patient care.”
The partnership operates on three core pillars: a dedication to high-quality, reliable results; exceptional service to patients and healthcare providers; and a financial model that supports ongoing investments in technology, workforce development, and lab facilities. Together, HNL Lab Medicine and bioMérieux aim to bring state-of-the-art diagnostics and operational expertise to the forefront of healthcare, offering a comprehensive model for superior laboratory medicine.
As part of HNL Lab Medicine’s Strategic Preferred Partnerships Program, this partnership with bioMérieux underscores the lab’s commitment to establishing long-term, impactful relationships with industry leaders. Through these partnerships, HNL Lab Medicine seeks to drive sustainable growth, enhance patient outcomes, and shape the future of diagnostic services.